MG
LYEL icon

Michael Gelband’s Lyell Immunopharma LYEL Stock Holding History

Michael Gelband’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,511
Closed -$262K – 1866
2025
Q4 		$262K Buy
+8,511
New +$190K ﹤0.01% 1338
2024
Q2 		– Sell
-12,254
Closed -$547K – 1785
2024
Q1 		$547K Buy
12,254
+9,709
+381% +$416K ﹤0.01% 1118
2023
Q4 		$99K Buy
+2,545
New +$91.6K ﹤0.01% 1352
2022
Q1 		– Sell
-775
Closed -$120K – 2470
2021
Q4 		$120K Buy
+775
New +$173K ﹤0.01% 1925
2021
Q3 		– Sell
-1,035
Closed -$336K – 2417
2021
Q2 		$336K Buy
+1,035
New +$340K ﹤0.01% 1675

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Michael Gelband's LYEL Position: Q1 2026 in Review

Michael Gelband sold out of Lyell Immunopharma (LYEL) in Q1 2026, closing a stake of 8,511 shares — an estimated $262K sold.

Michael Gelband first reported a position in LYEL in Q2 2021 and held it in 5 quarters. The position peaked at $547K in Q1 2024. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Michael Gelband reported no remaining Lyell Immunopharma position as of Q1 2026 after selling out during the quarter.
  • Michael Gelband sold 8,511 Lyell Immunopharma shares in Q1 2026, an estimated $262K.
  • Michael Gelband first reported a position in Lyell Immunopharma in Q2 2021 and held it in 5 quarters.
  • Michael Gelband's Lyell Immunopharma position peaked at $547K in Q1 2024.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.